

Multi-Cancer with CNV & RNA Fusion Panel

The oncoReveal® Multi-Cancer with CNV & RNA Fusion Panel is a combined DNA/RNA multi-cancer panel. The assay combines the DNA-based oncoReveal® Multi-Cancer v4 with CNV Panel with the oncoReveal® Multi-Cancer RNA Fusion v2 Panel allowing for joint sequencing. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry, designed by Pillar's AI-empowered VersaTile™ Primer Design tool, for efficient single-tube target enrichment.

Variants and CNVs detected from DNA

| ABL1 | CDKN2A | FBXW7 | GNAS | KIT | NPM1 | PTPN11 | SRC |
|---------|--------|---------|-------|--------|----------|---------|-------|
| AKTI | CSF1R | FGFR1 • | HNF1A | KRAS • | NRAS | RAC1 | STK11 |
| ALK | CTNNB1 | FGFR2• | HRAS | MAP2K1 | NTRK1 | RB1 | TP53 |
| APC | DDR2 | FGFR3• | IDH1 | MET ■ | NTRK2 | RET | VHL |
| ATM | EGFR - | FLT3 • | IDH2 | MLH1 | NTRK3 | ROS1 | |
| BRAF | ERBB2■ | FOXL2 | JAK2 | MPL | PDGFRA• | SMAD4 | |
| CCNE1 • | ERBB4 | GNA11 | JAK3 | MYC ■ | PIK3CA • | SMARCB1 | |
| CDH1 | EZH2 | GNAQ | KDR• | NOTCH1 | PTEN | SMO | |

CNVs detected and verified by NIST reference standard are indicated by

CNVs can also be detected in genes indicated by

Fusions and expression insights detected from RNA

Driver gene fusions (fusion partners not listed)

| ALŁ | (EGFR | FGFR2 | MET | NTRK1 | NTRK3 | PPARG | RAF1 | ROS1 |
|-----|--------|-------|------|-------|-------|--------|------|------|
| BRA | F ERG | FGFR3 | NRG1 | NTRK2 | PBX1 | PRKACA | RET | TFE3 |

3'/5' Expression Imbalance Ratio Assessed

| ALK | FGFR3 | NRG1 | NTRK1 | NTRK2 | NTRK3 | PBX1 | RET | ROS1 |
|---------|----------|--------|----------|---------|---------|--------|-----|-------|
| , (=: (| 1 01 110 | 111101 | 14114141 | 1111112 | 1111110 | 1 5/(1 | | 11001 |

Expression Control Genes

HMBS TBP

Simple NGS library prep workflow

Maintain control of samples and results with tiled amplification that can be performed in-house by any NGS lab

Sensitive and robust chemistry

Achieve variant detection as low as 1% VAF[†] even with limited input or poor sample quality

Reduced fullyloaded lab costs

Improve lab efficiency and reduce "no calls", repeat testing, and difficult interpretation decisions

For Research Use Only. Not for use in diagnostic procedures.



VAF, variant allele frequency

Multi-Cancer with CNV & RNA Fusion Panel

preparation

oncoReveal®

Simple workflow





Sequencing





Reporting

data analysis

Gene-specific PCR & cleanup **Indexing PCR** & cleanup

Quantitation &

Load sequencer

Gene-specific PCR & cleanup **Indexing PCR** & cleanup

Panel specifications

| r difer specifications | | | | |
|--|---|--|--|--|
| | oncoReveal® Multi-Cancer v4 with CNV | oncoReveal® Multi-Cancer RNA Fusion v2 | | |
| Enrichment chemistry | Multiplex PCR using tiled amplicons | | | |
| Number of pools | 2 pools | | | |
| Number of genes/amplicons | 60/341 | 18 genes and >80 partners, plus MET exon 14 skipping | | |
| Number of targets | Hotspots in 60 genes; CNVs for 14 genes; -33.1kb total size | Fusions in 18 driver genes; expression for 11 genes | | |
| Variant types | SNVs, small and medium indels, and CNVs | Fusion RNA transcripts | | |
| Average amplicon size | 143bp | 120bp | | |
| Recommended input range | 5ng to 80ng DNA | 20ng to 100ng RNA | | |
| Sample types | DNA from tissue, blood; or FFPE | RNA from FFPE or tissue; cfRNA | | |
| Mapping rate | 99.23% ± 0.3% | n/a | | |
| % on-target aligned reads | 99.5% ± 0.1% | n/a | | |
| Coverage uniformity (% targets with >0.2x mean coverage) | 98.2% ± 0.7% | n/a | | |
| Recommended reads per sample | ~1.4 million paired-end reads | ~50,000 paired-end reads per sample | | |
| Total assay time (from RNA to sequencer) | <10.5 hours | | | |

Mapping rate, percentage of on-target aligned reads, and coverage uniformity metrics are based on internal testing performed using reference standard materials

Ordering information

Select the panel AND one of the index kit options listed below.

| Panel | Part number |
|---|----------------|
| oncoReveal® Multi-Cancer with CNV and RNA Fusion Panel (48 reactions) | HNA-HS-1001-48 |

| Pillar Index Kit options | Reactions | Part number |
|-----------------------------------|--------------------------------|-----------------|
| Pillar Custom Index Primers Kit A | 32 Combinations, 96 reactions | IDX-PI-1001-96 |
| Pillar Custom Index Primers Kit D | 96 Combinations, 192 reactions | IDX-PI-1004-192 |

TO ORDER OR LEARN MORE: pillarbiosci.com

For research use only. Not for use in diagnostic procedures.

© 2022 Pillar Biosciences. Pillar®, SLIMamp®, PiVAT®, VersaTile™, and oncoReveal® are trademarks of Pillar Biosciences, Inc. Current as of 05.15.2025 | MK-0024-4 v3.2



Pillar Biosciences, Inc. 9 Strathmore Rd Natick, MA 01760 (800) 514-9307 info@pillarbiosci.com

